Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $70

Benzinga Newsdesk www.benzinga.com Negative 55.7%

Neg 55.7% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $71 to $70.